MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar sanjac20 (< 20) Submitted: 8/13/2013 2:08:21 AM : Outperform Start Price: $7.10 MNKD Score: +3.77

MNKD appears likely to get the US Food and Drug Administration's approval to market their leading inhalant delivered insulin named Afreeza which is much faster acting than injected insulin in diabetes therapy. Afreeza gets insulin into the bloodstream in about 15 minutes from the lipstick case sized inhaler device whereas needle injected insulin takes 45 minutes or more to begin modulating blood sugar in type II diabetics. Vastly better insulin delivery system in a world with some 370 million diabetics. Huge worldwide market potential.If Afreeza is approved by the Food and Drug regulators share prices could easily triple or more over the next year.

Featured Broker Partners


Advertisement